VEGFA Gene rs2010963: Blood Vessel Formation, Tissue Oxygenation, and Altitude Adaptation

When you exercise hard, your muscles send out a distress signal: they need more oxygen than existing blood vessels can deliver. The primary molecular response to this demand is vascular endothelial growth factor — VEGF — a protein that stimulates the growth of new capillaries directly into oxygen-starved tissue. The gene that produces VEGF, VEGFA, has common variants that affect how much of this protein your body makes.

The Role of VEGF in Exercise Adaptation

Aerobic training adaptations depend critically on angiogenesis — the formation of new capillaries in trained muscle tissue. More capillaries mean better oxygen delivery, faster lactate clearance, and greater endurance capacity over time. VEGF is the primary trigger for this capillary growth, released by muscle fibers in response to hypoxia and mechanical stress during exercise.

GG carriers produce more VEGF at baseline and in response to exercise, which may accelerate the capillarization response to aerobic training. Over months of consistent training, this translates to a potentially more efficient oxygen delivery network. CC carriers still adapt — VEGF is not the only angiogenic factor — but the stimulus magnitude is lower.

Altitude Adaptation

Altitude exposure — where oxygen partial pressure is reduced — is one of the strongest triggers for VEGF upregulation. The hypoxia-inducible factor (HIF) pathway directly activates VEGFA transcription in low-oxygen conditions, driving both red blood cell production and new capillary growth as compensatory responses.

GG carriers at the rs2010963 locus tend to mount a stronger VEGF response to altitude, which may explain observed differences in altitude acclimatization between individuals. Studies in high-altitude populations and in climbers show associations between VEGFA variants and symptoms of acute mountain sickness, as well as long-term altitude adaptation in groups like Tibetans and Andeans.

Wound Healing and Tissue Repair

Healing requires new blood vessel growth into damaged tissue. VEGF drives this process, and variants that affect VEGF production also affect healing rate. Studies in surgical patients show that higher VEGF producers (GG at rs2010963) have faster wound vascularization and tissue regeneration following injury.

Conversely, VEGF is also a driver of tumor angiogenesis — cancer cells exploit the same pathway to grow their own blood supply. This is why anti-VEGF drugs (bevacizumab/Avastin) are used as cancer treatments. VEGFA variants are being studied as predictors of both cancer risk and anti-VEGF treatment response.